SEC Form 4/A · accession 0000891293-16-000080
CTI BIOPHARMA CORP · CTIC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owner
James A Bianco
Officer — President and CEO · Director
Period of report
Dec 23, 2015
Accepted (ET)
Jan 8, 2016 · 6:30 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000891293
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1,F2 | $1.24 | Dec 23, 2015 | A | 2,700,000 | A | — | Dec 23, 2025 | Common Stock | 2,700,000 | 2,700,000 | D |
Explanation of responses
- F1This report amends the report filed on December 23, 2015 in order to correct the number of shares subject to the option grant reported in Table II.
- F2The option is scheduled to vest in eight semi-annual installments over the four-year period following the grant date, subject to the reporting person's continued employment or service with the issuer through the applicable vesting date.